|Bid||24.27 x 1000|
|Ask||23.94 x 1000|
|Day's Range||24.27 - 26.72|
|52 Week Range||20.26 - 28.51|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Phathom Pharmaceuticals, Inc. , a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that David Socks, President and CEO, will present at the Jefferies 2019 London Healthcare Conference on Wednesday, November 20 at 10:40 a.m.
Phathom Pharmaceuticals, Inc. , a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today the closing of its previously announced initial public offering of 10,997,630 shares of its common stock, which includes the exercise in full by the underwriters of their option to purchase 1,434,473 additional shares, ...
(Bloomberg) -- Phathom Pharmaceuticals Inc. rose 29.5% after expanding its initial public offering to raise $182 million, adding to a wave of biomedical and biotechnology going public.Shares of Phathom closed at $24.60 in first day of trading Friday, giving the company a market value of $678 million.Phathom, based in Buffalo Grove, Illinois, sold 9.56 million shares for $19 each on Thursday. The company earlier had marketed 7.9 million shares for $18 to $20.The listing is one of 38 by biotechnology or biomedical companies on U.S. exchanges this year. While those IPOs have accounted for only $5.3 billion of the total $47 billion raised, they made up about a quarter of the 156 listings, according to data compiled by Bloomberg.Cabaletta Bio Inc., which is developing treatments for autoimmune diseases, raised $75 million in its IPO Thursday. It priced its shares at $11, below the target range of $14 to $16. They closed at $10 on Friday.Phathom is focused on commercializing novel treatments for gastrointestinal diseases. The company lost $89 million in the six months ended June 30, according to its filings with the U.S. Securities and Exchange Commission.Its offering was led by Goldman Sachs Group Inc., Jefferies Financial Group Inc. and Evercore Inc. Its shares are trading on the Nasdaq Global Market under the symbol PHAT.(Updates with closing share price in second paragraph)To contact the reporter on this story: Michael Hytha in San Francisco at email@example.comTo contact the editors responsible for this story: Liana Baker at firstname.lastname@example.org, Michael Hytha, Matthew MonksFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that it has priced its initial public offering of 9,563,157 shares of its common stock at a public offering price of $19.00 per share. The gross proceeds to Phathom, before deducting underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $181.7 million. All of the common stock is being offered by Phathom.